IAM’s fourth annual Pharma & Biotech IP 2020 took place in London on January 28, 2020.
In the event the following panels were held:
- Avoiding costly IP mistakes
- The convergence between life sciences and tech
- Protecting the next generation of therapies
- Opportunities for IP monetisation
- Litigation masterclass
The second panel, the convergence between life sciences and tech, was moderated by E. Kerim Yardımcı. The panellists were Gareth Jones (Vice President, IP, BenevolentAI), Sergei Kurkin (Director, Senior Patent Counsel, UCB) and Timo Minssen (Managing Director, Centre for Advanced Studies in Biomedical Innovation Law, University of Copenhagen).
The panel consisted of four sections; namely, (i) Protecting IP & ownership, (ii) competition Law, (iii) protecting & sharing data and (iv) building team to meet the new challenges & collaboration.
One of the highlights of the panel was the increasing use of artificial intelligence (AI) in areas of life sciences and technology and the protection ways for AI inventions. For biotech companies choosing trade secret or patenting for protection was still a matter of discussion. Panellists also referred to the challenges in protecting software-implemented inventions as well as AI inventions. These discussions were held both in IP and competition law perspectives.
Another topic was the tools for data protection especially in innovation and competition implications. The panellists discussed the challenges in case of collaborations of projects between biotech/pharma and tech companies. For collaborations, the main concerns were building strategies for IP teams and handling the IP. As the mergers of sector players keeps getting bigger, which party shall be the owner and how far the other party shall have access to these data becomes more of an issue.